LEXEO Therapeutics Reports the Completion of First Cohort and Dosing in Second Cohort in P-I/II Trial (SUNRISE-FA) of LX2006 for Friedreich’s Ataxia Cardiomyopathy
Shots:
- The company has completed the first dose cohort & dosing of 1st patient in the second dose cohort in the P-I/II trial (SUNRISE-FA) evaluating LX2006 (IV) in patients with FA cardiomyopathy
- LX2006 was found to be well tolerated with no unexpected events or toxicities in 1st dose cohort. In P-I/II trial, long-term safety and efficacy will be evaluated for an additional 4yrs. upon completion of the initial trial resulting in data from a total of 5yr. post-LX2006 treatment. The results are expected in H1’24
- LX2006 received RPD designation & ODD from the US FDA for FA. The therapy showed an improvement in cardiac function & survival along with a favorable safety profile in preclinical studies & reversed the cardiac abnormalities in FA disease models
Ref: Globe Newswire | Image: Lexeo
Related News:- LEXEO Receives the US FDA’s IND Clearance of LX2006 for the Treatment of Friedreich’s Ataxia Cardiomyopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
